Home >Companies >News >AstraZeneca gets DCGI approval to import, market Selumetinib capsules
Listen to this article

AstraZeneca Pharma India has received the approval of Drug Controller General of India to import and sell Selumetinib capsules in the country, the company said in a regulatory filing on Sunday.

“AstraZeneca Pharma India Limited has received import and market permission in Form CT-20 from the Drugs Controller General of India (DCGI) for Selumetinib 10 mg and 25 mg capsule," the filing read.

Selumetinib capsules in 10 mg and 25 mg configurations are used for treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

“The receipt of this permission paves way for the launch of Selumetinib 10 mg and 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses," AstraZeneca said.


Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
My ReadsRedeem a Gift CardLogout